HARP Stock Price, Harpoon Therapeutics Inc Quote, Chart

Market Summary

USD23.01

Market Closed

HARP Stock Price

View Fullscreen

HARP RSI Chart

HARP Valuation

Market Cap

389.6M

Price/Earnings (Trailing)

-12.77

Price/Sales (Trailing)

10.43

Price/Free Cashflow

-5.61

HARP Price/Sales (Trailing)

HARP Profitability

Return on Equity

-671.61%

Return on Assets

-64.1%

Free Cashflow Yield

-17.84%

HARP Fundamentals

HARP Revenue

Revenue (TTM)

37.3M

Rev. Growth (Yr)

-67.33%

Rev. Growth (Qtr)

-78%

HARP Earnings

Earnings (TTM)

-30.5M

Earnings Growth (Yr)

84.52%

Earnings Growth (Qtr)

-269.84%

Breaking Down HARP Revenue

Last 7 days

0.3%

Last 30 days

3.1%

Last 90 days

157.4%

Trailing 12 Months

194.6%

How does HARP drawdown profile look like?

HARP Financial Health

Current Ratio

1.89

HARP Investor Care

Shares Dilution (1Y)

409.57%

Diluted EPS (TTM)

-8.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	34.6M	46.5M	37.3M	0
2022	20.6M	23.0M	32.2M	31.9M
2021	23.2M	26.2M	26.8M	23.7M
2020	8.0M	9.7M	12.2M	17.4M
2019	4.3M	4.3M	4.6M	5.8M
2018	1.9M	3.2M	4.4M	4.8M
2017	0	0	0	708.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Harpoon Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	new leaf biopharma opportunities ii, l.p.	back to issuer	-	-	-395,783	-
Mar 11, 2024	chin mark	back to issuer	-	-	-13,224	-
Mar 11, 2024	walker luke nathaniel	back to issuer	-	-	-135,000	chief medical officer
Mar 11, 2024	lanza frank j	back to issuer	-	-	-18,734	principal fin. & acctng ofc.
Mar 11, 2024	robbins andrew r	back to issuer	-	-	-5,000	-
Mar 11, 2024	drachman jonathan g	back to issuer	-	-	-5,415	-
Mar 11, 2024	eastland julia marie	acquired	-	-	31,250	president and ceo
Mar 11, 2024	eastland julia marie	back to issuer	-	-	-269,381	president and ceo
Mar 11, 2024	myers scott dunseth	back to issuer	-	-	-22,665	-
Mar 11, 2024	hunt ronald	back to issuer	-	-	-10,000	-

Which funds bought or sold HARP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Allworth Financial LP	sold off	-100	-455	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	676	9,548,940	10,005,800	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	1,113,080	1,113,080	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	sold off	-100	-29.00	-	-%
Feb 15, 2024	BARCLAYS PLC	new	-	1,000	1,000	-%
Feb 14, 2024	CAXTON CORP	new	-	129,291	129,291	0.70%
Feb 14, 2024	RA CAPITAL MANAGEMENT, L.P.	new	-	17,055,000	17,055,000	0.27%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	added	138	246,517	289,537	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	307,468	307,468	-%

Are Funds Buying or Selling HARP?

Are funds buying HARP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HARP

No. of Funds

Unveiling Harpoon Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	glazer capital, llc	0.00%	0	SC 13G
Mar 13, 2024	gamco investors, inc. et al	0.00%	5	SC 13D/A
Mar 11, 2024	merck sharp & dohme llc	100%	1,000	SC 13D/A
Feb 27, 2024	gamco investors, inc. et al	4.03%	862,549	SC 13D
Feb 21, 2024	arix bioscience plc	1.50%	323,893	SC 13D/A
Feb 14, 2024	citadel advisors llc	5.9%	6	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	1,712,792	SC 13G/A
Feb 13, 2024	new leaf ventures iii, l.p.	-	481,533	SC 13G/A
Feb 13, 2024	vanguard group inc	5.20%	880,017	SC 13G
Feb 12, 2024	mpm bioventures 2014, l.p.	1.6%	265,709	SC 13D/A

Recent SEC filings of Harpoon Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Mar 21, 2024	15-12G	15-12G
Mar 18, 2024	SC 13G	Major Ownership Report
Mar 13, 2024	SC 13D/A	13D - Major Acquisition
Mar 11, 2024	POS AM	POS AM
Mar 11, 2024	S-8 POS	Employee Benefits Plan
Mar 11, 2024	POS AM	POS AM
Mar 11, 2024	POS AM	POS AM
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading

Peers (Alternatives to Harpoon Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Harpoon Therapeutics Inc News

Latest updates

Harpoon Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-78.0%	4,448	20,221	8,583	4,089	13,617	8,303	5,906	4,325	4,484	5,838	9,007	7,492	3,893	2,762	3,297	2,234	1,417	1,063	1,063	1,063	1,063
Operating Expenses	-6.4%	16,587	17,728	19,348	22,801	25,506	25,714	26,219	25,866	21,159	22,606	70,774	18,989	17,485	15,869	16,432	17,039	18,026	13,705	15,214	10,932	7,909
S&GA Expenses	12.1%	4,262	3,803	4,185	3,854	4,529	5,063	5,401	5,202	4,186	4,335	4,604	3,924	4,428	3,945	3,913	4,333	8,493	3,734	5,832	2,215	1,942
R&D Expenses	1.1%	12,325	12,196	15,163	18,947	20,977	20,651	20,818	20,664	16,973	18,271	16,216	15,065	13,057	11,924	12,519	12,706	9,533	9,971	9,382	8,717	5,967
Interest Expenses	31.2%	2,046	1,560	138	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-269.8%	-1,802	1,061	-11,338	-18,419	-11,640	-17,351	-20,321	-21,551	-16,682	-16,764	-61,724	-11,357	-13,307	-12,692	-12,552	-14,269	-15,907	-11,817	-13,579	-9,729	-6,761
Net Income Margin	5.8%	-0.82*	-0.87*	-1.70*	-2.12*	-2.20*	-3.30*	-3.66*	-4.93*	-3.97*	-3.93*	-4.28*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-9.5%	-16,620	-15,176	-19,286	-18,418	-24,217	-22,253	-24,641	-16,888	-20,678	-66,566	-18,122	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2017Q4
Assets	-24.7%	48.00	63.00	81.00	74.00	83.00	109	132	155	175	196	261	172	183	197	162	177	142	157	167	103	32.00
Current Assets	-30.1%	34.00	49.00	64.00	55.00	69.00	94.00	117	138	156	176	234	130	158	175	129	151	123	137	141	90.00	30.00
Cash Equivalents	-45.9%	18.00	33.00	61.00	52.00	51.00	69.00	51.00	45.00	43.00	77.00	71.00	21.00	23.00	35.00	36.00	89.00	57.00	52.00	96.00	90.00	29.00
Net PPE	-3.9%	4.00	4.00	6.00	7.00	8.00	8.00	9.00	9.00	9.00	9.00	10.00	10.00	10.00	11.00	11.00	11.00	12.00	12.00	6.00	3.00	2.00
Liabilities	-28.5%	43.00	60.00	80.00	68.00	67.00	82.00	91.00	97.00	98.00	105	159	118	123	125	79.00	82.00	35.00	35.00	33.00	26.00	19.00
Current Liabilities	-28.5%	18.00	25.00	44.00	52.00	54.00	58.00	59.00	59.00	55.00	55.00	98.00	48.00	45.00	39.00	24.00	23.00	17.00	15.00	12.00	12.00	7.00
Shareholder's Equity	51.5%	5.00	3.00	1.00	5.00	17.00	27.00	41.00	58.00	77.00	91.00	102	54.00	61.00	72.00	83.00	94.00	107	122	134	-	-
Retained Earnings	-0.5%	-364	-362	-363	-352	-334	-322	-305	-284	-263	-246	-229	-168	-156	-143	-130	-118	-103	-87.99	-76.17	-62.59	-35.22
Additional Paid-In Capital	0.9%	369	366	365	358	351	349	347	343	340	337	332	222	217	215	214	212	211	210	210	9.00	8.00
Shares Outstanding	8.2%	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	27.00	-	-	-	263	-	-	-	142	-	-	-	126	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	-8.9%	-16,529	-15,176	-19,286	-18,390	-23,951	-21,603	-25,238	-16,833	-20,678	-66,566	-18,077	-15,167	-13,487	37,555	-17,517	33,718	-11,237	-12,947	-12,425	-6,444	-7,102
Share Based Compensation	-13.7%	918	1,064	1,134	1,493	1,779	2,521	2,843	2,649	2,340	2,337	2,136	1,331	1,504	1,178	847	643	592	467	369	211	174
Cashflow From Investing	91.7%	-1,029	-12,373	2,438	14,247	5,650	39,381	30,459	18,686	-14,122	69,690	-39,900	10,445	331	-39,086	-35,316	-2,271	15,808	-31,203	-51,649	-157	-191
Cashflow From Financing	295.6%	2,032	-1,039	26,619	5,389	101	52.00	830	47.00	380	2,954	108,142	3,241	1,069	101	265	525	99.00	318	70,507	68,236	20,058

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HARP Income Statement

2023-09-30

Condensed Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Total revenue	$ 4,448	$ 13,617	$ 33,252	$ 27,826
Revenue, Product and Service [Extensible Enumeration]	Total revenue	Total revenue	Total revenue	Total revenue
Operating expenses
Research and development	$ 12,325	$ 20,977	$ 39,684	$ 62,446
General and administrative	4,262	4,529	12,250	14,993
Impairment of long-lived assets	0	0	1,729	0
Total operating expenses	16,587	25,506	53,663	77,439
Loss from operations	(12,139)	(11,889)	(20,411)	(49,613)
Interest income, net	480	289	1,520	433
Interest expense	(2,046)	0	(3,744)	0
Other income (expense), net	11,903	(40)	10,556	(132)
Net loss attributable to common stockholders	(1,802)	(11,640)	(12,079)	(49,312)
Other comprehensive loss:
Net unrealized (loss) gain on marketable securities	(4)	28	4	19
Comprehensive loss	$ (1,806)	$ (11,612)	$ (12,075)	$ (49,293)
Net loss attributable to common stockholders per share, basic	$ (0.46)	$ (3.52)	$ (3.17)	$ (14.95)
Net loss attributable to common stockholders per share, diluted	$ (0.46)	$ (3.52)	$ (3.17)	$ (14.95)
Weighted-average shares used in computing net loss per share, basic	3,947,995	3,306,215	3,807,955	3,299,357
Weighted-average shares used in computing net loss per share, diluted	3,947,995	3,306,215	3,807,955	3,299,357

HARP Balance Sheet

2023-09-30

Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 17,738	$ 51,614
Short-term marketable securities	13,870	1,498
Prepaid expenses and other current assets	2,688	1,615
Total current assets	34,296	54,727
Property and equipment, net	3,527	7,237
Operating lease right-of-use assets	8,857	10,854
Other assets	898	911
Total assets	47,578	73,729
Current liabilities
Accounts payable	3,435	4,712
Accrued liabilities	11,697	14,361
Deferred revenue, current	0	30,937
Operating lease liabilities, current	2,974	2,423
Total current liabilities	18,106	52,433
Deferred revenue, noncurrent	0	2,314
Operating lease liabilities, net of current portion	11,530	13,583
Embedded redemption liability	4,574	0
Series A mandatorily redeemable preferred stock	8,827	0
Total liabilities	43,037	68,330
Commitments and contingencies (Note 6)
Stockholders' equity
Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2023 and December 31, 2022; 4,108,769 shares and 3,578,668 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	1	4
Additional paid-in capital	369,141	357,921
Accumulated other comprehensive income (loss)	1	(3)
Accumulated deficit	(364,602)	(352,523)
Total stockholders' equity	4,541	5,399
Total liabilities and stockholders' equity	$ 47,578	$ 73,729

About Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

CEO	Ms. Julie M. Eastland M.B.A.
WEBSITE	harpoontx.com
INDUSTRY	Biotechnology
EMPLOYEES	46

Harpoon Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Harpoon Therapeutics Inc? What does HARP stand for in stocks?

HARP is the stock ticker symbol of Harpoon Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harpoon Therapeutics Inc (HARP)?

As of Mon Mar 11 2024, market cap of Harpoon Therapeutics Inc is 389.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HARP stock?

You can check HARP's fair value in chart for subscribers.

What is the fair value of HARP stock?

You can check HARP's fair value in chart for subscribers. The fair value of Harpoon Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Harpoon Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HARP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Harpoon Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HARP is over valued or under valued. Whether Harpoon Therapeutics Inc is cheap or expensive depends on the assumptions which impact Harpoon Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HARP.

What is Harpoon Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 11 2024, HARP's PE ratio (Price to Earnings) is -12.77 and Price to Sales (PS) ratio is 10.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HARP PE ratio will change depending on the future growth rate expectations of investors.